Clinical Trials Browser

Neoplasms, Plasma Cell

NCT04234022 2026-04-09

Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma

Recruiting

70 enrolled

Plasma cell

Multiple Myeloma

NCT06971848 2026-03-30

ETCABIO

Phase NA Not yet recruiting

70 enrolled

GastrointestinalLymphoidOther hematologic neoplasmOther solid neoplasmPlasma cellThoracic

Immunoglobulin Light-chain Amyloidosis, Esophageal Squamous Cell Carcinoma, Mesothelioma, Malignant, Carcinoma, Bronchogenic, Heart Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Follicular, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Cholangiocarcinoma, Neoplasms, Plasma Cell

Clinical Trials

REMAKE

Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma

ETCABIO

MSTH-CAR001

EHCancer

Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen

UCAR-T_MM-XA

PNRR-2022-1237

ALHERT

MMYLIFE

Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia

Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research

IPoD-790

Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells

KEEPER

ECAR01

MMOMICS

FKTMM2022

Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies

Two Schemes Response in Multiple Myeloma

Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients

Integrative Therapies in Multiple Myeloma

Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies

Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow Transplantation

RAT-HEMATO

Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma

A Single-centre Prospective Study to Explore the Role of Frailty in Patients With Multiple Myeloma.

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents

KyDaR

The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19

CTFEA Myeloma Study

Velcadito

RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma

MM-POM-2018

BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma

Study of BCMA CAR-T in Multiple Myeloma

Lonquek for Autologous Stem Cell Mobilization

Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies

Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma

Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma

BIPN

Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients

The Optimal Timing of a Second Autologous Peripheral Blood Stem Cell Transplantation in Patients (<61 Years) With Multiple Myeloma

Atorvastatin in Myeloma